RxDoctor Payments Data

Frank Leiva, MD

Internal Medicine · Orlando, FLNPI 1295836906

Payments from drug & device makers

$3,972in general payments, 2019–2025

Across 197 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$568
  • AstraZeneca$564
  • Novo Nordisk$498
  • Pfizer$358
  • Lilly USA, LLC$347
  • AbbVie$285
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,94699%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,972 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,747
Medicare patients
192
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$86,601
OzempicSemaglutide41$80,334
MounjaroTirzepatide34$44,555
TrulicityDulaglutide31$44,497
FarxigaDapagliflozin Propanediol40$33,784
JardianceEmpagliflozin32$31,006
JanuviaSitagliptin Phosphate20$21,303
TradjentaLinagliptin21$18,782
XareltoRivaroxaban11$8,702
Breo ElliptaFluticasone/Vilanterol13$6,232
SynthroidLevothyroxine Sodium38$4,377
Levothyroxine Sodium356$2,485
Atorvastatin Calcium221$1,964
Testosterone Cypionate60$1,859
Rosuvastatin Calcium215$1,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$347$89,05265 claims
PfizerEliquis$358$86,60184 claims
Novo NordiskOzempic$498$80,33441 claims
Boehringer IngelheimJardiance, Tradjenta$165$49,78853 claims
AstraZenecaFarxiga$564$33,78440 claims
Johnson & JohnsonXarelto$131$8,70211 claims
GSKBreo Ellipta$72$6,23213 claims
AbbVieSynthroid$285$4,37738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →